| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $4...
Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus.
Twist Bioscience (NASDAQ:TWST) sees Q1 sales of $100.000 million-$101.000 million vs $100.337 million analyst estimate.
Twist Bioscience (NASDAQ:TWST) sees FY2026 sales of $425.000 million-$435.000 million vs $374.691 million analyst estimate.
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(...